CYTK - Cytokinetics, Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
562.62M
Enterprise Value 3
443.11M
Trailing P/E
N/A
Forward P/E 1
-4.71
PEG Ratio (5 yr expected) 1
-0.31
Price/Sales (ttm)
18.13
Price/Book (mrq)
N/A
Enterprise Value/Revenue 3
14.28
Enterprise Value/EBITDA 6
-4.61

Trading Information

Stock Price History

Beta (3Y Monthly) 1.51
52-Week Change 319.97%
S&P500 52-Week Change 318.18%
52 Week High 314.94
52 Week Low 35.75
50-Day Moving Average 39.79
200-Day Moving Average 311.35

Share Statistics

Avg Vol (3 month) 3747.97k
Avg Vol (10 day) 3837.74k
Shares Outstanding 559.16M
Float 51.07M
% Held by Insiders 17.32%
% Held by Institutions 175.19%
Shares Short (Nov 15, 2019) 47.1M
Short Ratio (Nov 15, 2019) 47.77
Short % of Float (Nov 15, 2019) 415.64%
Short % of Shares Outstanding (Nov 15, 2019) 412.01%
Shares Short (prior month Oct 15, 2019) 43.88M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 26/1
Last Split Date 3Jun 25, 2013

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-311.34%

Management Effectiveness

Return on Assets (ttm)-28.92%
Return on Equity (ttm)-729.94%

Income Statement

Revenue (ttm)31.03M
Revenue Per Share (ttm)0.55
Quarterly Revenue Growth (yoy)-43.10%
Gross Profit (ttm)-57.63M
EBITDA -96.04M
Net Income Avi to Common (ttm)-117.52M
Diluted EPS (ttm)-2.08
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)166.04M
Total Cash Per Share (mrq)2.81
Total Debt (mrq)52.6M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)8.20
Book Value Per Share (mrq)-0.34

Cash Flow Statement

Operating Cash Flow (ttm)-84.18M
Levered Free Cash Flow (ttm)-61.1M